Pharmaceutical development and manufacturing company Pegasus Laboratories Inc announced on Thursday that it has received full approval from the US Food and Drug Administration (FDA) for KBroVet (potassium bromide chewable tablets) for the control of seizures associated with idiopathic epilepsy (IE) in dogs.
According to Pegasus, with this approval KBroVet becomes the first FDA fully approved pharmaceutical specifically indicated for the control of seizures associated with idiopathic epilepsy in dogs, representing a significant advancement for veterinarians and pet owners managing this chronic neurological condition.
In addition, KBroVet is only the second animal health pharmaceutical, across any condition or disease, to successfully transition from conditional FDA approval to full FDA approval.
The once-daily chewable tablets are formulated specifically for dogs and are available in 60-count and 180-count bottles.
Iterion Therapeutics reports first patient dosed in clinical study of tegavivint
FDA accepts Takeda's oveporexton NDA with priority review for narcolepsy type 1
Innocan Pharma reports findings from clinical study of LPT-CBD in dogs
Lunai Bioworks starts new oncology collaboration with clinical-stage partner
Median Technologies secures FDA clearance for AI lung cancer screening software
Sanofi's rilzabrutinib receives FDA breakthrough and Japan orphan designations for rare anaemia
Ascentage Pharma receives China IND clearance for BTK degrader APG‑3288
FDA issues EUA for Boehringer Ingelheim's IVOMEC (ivermectin) 1% Injection
Cumberland Pharmaceuticals secures FDA Fast Track status for DMD heart‑disease therapy ifetroban
Hologic receives FDA approval for Aptima HPV assay as primary screening option
AbbVie submits FDA and EMA applications for new upadacitinib indication in NSV
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer